Alexza is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of underserved medical needs. Our current focus is on central nervous system conditions.
Strategically, Alexza is focused on finding new therapeutic solutions for conditions that would benefit from rapid, precise and non-invasive treatment. For certain conditions, patients and physicians are in need of products with rapid onset of effect, ease of use, non-invasive administration and dosage titration by patients which the Staccato® system may be able to address. The Staccato platform has the potential to address these needs and to provide flexibility to deliver the most important pharmaceutical benefits of therapeutics in an innovative way.
Alexza's products and development pipeline are based on the Staccato system, a hand-held inhaler designed to deliver a pure drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. Pipeline product candidates include AZ-002 (Staccato alprazolam) for the management of epilepsy in patients with acute repetitive seizures, AZ-003 (Staccato fentanyl) for cancer breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of patients with middle of the night insomnia.
ADASUVE® is Alexza's first commercial product. ADASUVE is approved for marketing in 42 countries and has been submitted for approval in seven additional countries. ADASUVE has been launched and is currently available in 23 countries.
Alexza Pharmaceuticals is a wholly owned subsidiary of Ferrer Therapeutics, Inc., which is a wholly owned subsidiary of Ferrer.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.